SERPINA1 and alpha 1-antitrypsin deficiency: Our in vitro model captured the enzymatic footprint changes consistent with clinical observations in patients and provides a quick and reproducible way to assess the cellular response effects of putative therapeutic compounds for the NSP axis and AAT at levels consistent with AATD before and during augmentation therapy.